RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%
- RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with potential to address unmet medical need
- Once-daily oral RAD001 directly targets and continuously inhibits mTOR, a protein that controls tumor cell division and blood vessel growth
- RAD001 is currently being studied in multiple types of cancer including neuroendocrine, breast, gastric, lung, and lymphoma<img src="http://feeds.foxbusiness.com/~r/foxbusiness/latest/~4/293265229" height="1" width="1"/><img src="http://feeds.foxnews.com/~r/foxnews/business/~4/293271139" height="1" width="1"/>
http://feeds.foxnews.com/~r/foxnews/business/~3/293271139/